RPRX
Royalty Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RPRX
Royalty Pharma Plc
The leading provider of funding solutions for life sciences innovation
110 East 59th Street, New York, New York 10022
--
Royalty Pharma plc was incorporated under the laws of England and Wales on 6 February 2020. The company is the largest buyer of biopharmaceutical royalties and a major funder of innovation in the biopharmaceutical industry. Since its inception in 1996, the company has been a pioneer in the royalty market, partnering with innovators from academic institutions, research hospitals and non-profit organizations (from small and medium-sized biotech companies to leading global pharmaceutical companies). The company collects a series of royalties that entitle them to make payments directly based on top-line sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. The company directly or indirectly funds innovation in the biopharmaceutical industry when they partner with companies to co-finance late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when they receive existing royalties from original innovators.
Earnings Call
Q1/2025
Estimate EPS0.95
Actual EPS0.41
Estimate Revenue724.69M
Actual Revenue839.00M
Royalty Pharma's Q1 2025: Navigating Contradictions in Regulatory Challenges, Tariffs, and Capital Strategy
May 19,2025 08:23
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.02
Actual EPS1.14
Estimate Revenue693.74M
Actual Revenue579.00M
Royalty Pharma's Q2 2025: Navigating Contradictions in Policy Impact, Dispute Resolutions, and Strategic Shifts
Aug 06,2025 04:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RPRX has released its 2025 Q3 earnings. EPS was reported at 0.51, versus the expected 1.04, missing expectations. The chart below visualizes how RPRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RPRX has released its 2025 Q3 earnings report, with revenue of 609.29M, reflecting a YoY change of 7.90%, and net profit of 444.21M, showing a YoY change of -44.91%. The Sankey diagram below clearly presents RPRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
